FDA clears Aprea Therapeutic’s Investigational New Drug (IND) application (IND 169359) for oral WEE1 Inhibitor, APR-1051
Aprea to initiate the Phase 1 ACESOT-1051 trial. Learn more

We’re on a Mission to Increase the Specificity and Reduce the Toxicity of DDR Inhibitors

Our therapeutic assets—and the proprietary technologies we use to validate them—reflect our commitment to giving cancer patients more choices.

MOLECULETARGETINDICATIONBIOMARKERPreclinicalIND-EnablingPhase 1Anticipated Milestones
ATRN-119ATRAdvanced Solid TumorsRepliBiom1 Profiling
Complete P 1/2a dose escalation | 4Q 2024
Recommended P 2 dose | 1Q 2025
Initiate dose expansion | 1Q 2025
Additional open-label efficacy data | 3Q 2025
APR-1051WEE1Ovarian Cancer, Others CCNE Amplification, Others
First patient enrolled | 1H 2024
Open-label efficacy data | 2Q 2025
Recommended P 2 dose | 2H 2025
APR-DDRiDDR TargetAdvanced Solid TumorsUndisclosed
Identify lead candidate | Q2 2024
1 RepliBiom – a synthetic lethality discovery platform

Proprietary Discovery Technologies

Our integrated, proprietary discovery technologies are every bit as innovative as the DDR research they make possible. These technologies make our drugs as specific for their targets as possible and identify genetic vulnerabilities in cancers that cause selective sensitivity to these drugs. We believe these approaches will allow our drugs to kill cancers, while leaving normal patient tissues less affected. The products and/or investigational product candidates listed on this page are not approved by the FDA or have not been approved for the above-referenced indications, and the safety and effectiveness of such has not been established.

The RepliBiom Platform Enables Us to Identify Sensitizing Features in Cancers and Novel DDR Targets

RepliBiom is an integrated proteomic, genomic and computational platform that identifies proteins that both participate in the molecular response to drug treatment and are highly mutated in cancers. Aprea uses the platform to identify defects in cancers that cause sensitivity to our drugs. In addition, this platform is being used to discover novel combination therapies and new drug targets to advance its drug development programs.

ATRIZE Enables Our Team to Quickly Optimize Our DDR Inhibitors

An innovative, high through-put system that detects the disruption of DNA synthesis and DDR activation, making it ideal for DDR inhibitor drug screening. ATRIZE may significantly reduce the time required to discover active drug candidates and optimize their design for precision cancer therapy.

SCET helps us develop highly potent anticancer candidates with decreased off-target activities.

SCET (Small Cyclic Enzyme Targeting) is a medicinal chemistry cyclization approach to generating highly potent and selective enzyme inhibitors. SCET enables the design and synthesis of novel conformationally constrained drug candidates with potentially higher affinity and specificity for the target enzyme.

To learn more about our current trials